We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In the last reported quarter, the company’s adjusted earnings per share (EPS) of 51 cents surpassed the Zacks Consensus Estimate by 59.38%. Earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 45.12%.
Q4 Estimates for VCYT
The Zacks Consensus Estimate for revenues is pegged at $138.7 million, suggesting a 16.9% rise from the year-ago reported figure.
The Zacks Consensus Estimate for EPS of 41 cents indicates a 13.9% year-over-year increase.
Estimate Revision Trend Ahead of VCYT’s Q4 Earnings
Estimates for earnings have moved north 2.5% in the past 30 days.
Here’s a brief recap of the company’s performance leading up to this announcement.
VCYT: Factors at Play
Testing
The company’s core testing business is likely to have delivered solid revenue growth in the fourth quarter, supported by continued strength in both Decipher and Afirma volumes. Afirma volumes might have grown, driven by a steady stream of new account wins and increased utilization per account.
Decipher Prostate delivered approximately 26,700 tests in the third quarter, marking its 14th consecutive quarter of more than 25% year-over-year volume growth. We expect this trend to have persisted in the fourth quarter as well. Test volume may have increased due to growing clinical adoption across risk categories, as physicians increasingly recognize its utility in guiding treatment decisions.
Test volumes in the high-risk localized segment might have also increased, indicating accelerated traction in this key category. Ongoing research activity remains robust, with 23 new abstracts and publications on Decipher Prostate and GRID, bringing the cumulative total to 240 publications and reinforcing the growing body of clinical evidence supporting the platform.
Product
Third-quarter product volume was approximately 2,200 tests and product revenues grew 4% year over year. We expect this trend to have persisted in the fourth quarter as well.
However, in the third earnings call, management stated that it expects product gross margin to decline in the fourth quarter due to its transition to a contract manufacturing model.
Revenues in this segment are expected to decrease, given the Veracyte SAS restructuring and liquidation proceedings. Gross margin is also expected to be in negative.
Earnings Whispers for VCYT Stock
Per our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates, which is exactly the case here:
Earnings ESP: Vercayte has an Earnings ESP of +7.98%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Vercayte currently carries a Zacks Rank #2.
Other Key MedTech Picks
Here are some other medical stocks worth considering, as these, too, have the right combination of elements to post an earnings beat this time around:
AngioDynamics (ANGO - Free Report) has an Earnings ESP of +4.76% and a Zacks Rank #1. The company is set to release third-quarter fiscal 2026 results soon.
ANGO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 82.14%. The Zacks Consensus Estimate for the company’s fiscal third-quarter EPS suggests a decrease of 466.3% from the year-ago figure.
Globus Medical (GMED - Free Report) has an Earnings ESP of +3.92% and a Zacks Rank #2. The company is expected to release fourth-quarter 2025 results soon.
GMED’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 16.24%. The Zacks Consensus Estimate for the company’s fourth-quarter EPS implies a surge of 26.2% from the year-ago reported figure.
Merit Medical Systems (MMSI - Free Report) has an Earnings ESP of +2.09% and a Zacks Rank #2. The company is slated to release fourth-quarter 2025 results on Feb. 24.
MMSI’s earnings topped estimates in each of the trailing four quarters, the average surprise being 14.1%. The Zacks Consensus Estimate for the company’s fourth-quarter EPS calls for an increase of 3.2% from the year-ago quarter’s figure.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Here's How Veracyte Stock Is Placed Ahead of Q4 Earnings
Key Takeaways
Veracyte, Inc. (VCYT - Free Report) is scheduled to report fourth-quarter 2025 results on Feb. 25, after market close.
In the last reported quarter, the company’s adjusted earnings per share (EPS) of 51 cents surpassed the Zacks Consensus Estimate by 59.38%. Earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 45.12%.
Q4 Estimates for VCYT
The Zacks Consensus Estimate for revenues is pegged at $138.7 million, suggesting a 16.9% rise from the year-ago reported figure.
The Zacks Consensus Estimate for EPS of 41 cents indicates a 13.9% year-over-year increase.
Estimate Revision Trend Ahead of VCYT’s Q4 Earnings
Estimates for earnings have moved north 2.5% in the past 30 days.
Here’s a brief recap of the company’s performance leading up to this announcement.
VCYT: Factors at Play
Testing
The company’s core testing business is likely to have delivered solid revenue growth in the fourth quarter, supported by continued strength in both Decipher and Afirma volumes. Afirma volumes might have grown, driven by a steady stream of new account wins and increased utilization per account.
Decipher Prostate delivered approximately 26,700 tests in the third quarter, marking its 14th consecutive quarter of more than 25% year-over-year volume growth. We expect this trend to have persisted in the fourth quarter as well. Test volume may have increased due to growing clinical adoption across risk categories, as physicians increasingly recognize its utility in guiding treatment decisions.
Test volumes in the high-risk localized segment might have also increased, indicating accelerated traction in this key category. Ongoing research activity remains robust, with 23 new abstracts and publications on Decipher Prostate and GRID, bringing the cumulative total to 240 publications and reinforcing the growing body of clinical evidence supporting the platform.
Product
Third-quarter product volume was approximately 2,200 tests and product revenues grew 4% year over year. We expect this trend to have persisted in the fourth quarter as well.
However, in the third earnings call, management stated that it expects product gross margin to decline in the fourth quarter due to its transition to a contract manufacturing model.
Veracyte, Inc. Price and EPS Surprise
Veracyte, Inc. price-eps-surprise | Veracyte, Inc. Quote
Biopharmaceutical and other
Revenues in this segment are expected to decrease, given the Veracyte SAS restructuring and liquidation proceedings. Gross margin is also expected to be in negative.
Earnings Whispers for VCYT Stock
Per our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates, which is exactly the case here:
Earnings ESP: Vercayte has an Earnings ESP of +7.98%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Vercayte currently carries a Zacks Rank #2.
Other Key MedTech Picks
Here are some other medical stocks worth considering, as these, too, have the right combination of elements to post an earnings beat this time around:
AngioDynamics (ANGO - Free Report) has an Earnings ESP of +4.76% and a Zacks Rank #1. The company is set to release third-quarter fiscal 2026 results soon.
ANGO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 82.14%. The Zacks Consensus Estimate for the company’s fiscal third-quarter EPS suggests a decrease of 466.3% from the year-ago figure.
Globus Medical (GMED - Free Report) has an Earnings ESP of +3.92% and a Zacks Rank #2. The company is expected to release fourth-quarter 2025 results soon.
GMED’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 16.24%. The Zacks Consensus Estimate for the company’s fourth-quarter EPS implies a surge of 26.2% from the year-ago reported figure.
Merit Medical Systems (MMSI - Free Report) has an Earnings ESP of +2.09% and a Zacks Rank #2. The company is slated to release fourth-quarter 2025 results on Feb. 24.
MMSI’s earnings topped estimates in each of the trailing four quarters, the average surprise being 14.1%. The Zacks Consensus Estimate for the company’s fourth-quarter EPS calls for an increase of 3.2% from the year-ago quarter’s figure.